Research advances and treatment perspectives of pancreatic adenosquamous carcinoma

Zhang, Wen; Zhang, Jing; Liang, Xijun; Ding, Jin

doi:10.1007/s13402-022-00732-2

Cited by 5 publications

(3 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiomics, offering better disease characterization by extracting high-dimensional features beyond visual assessment ( 34 ), has been a promising method to evaluate the infiltration levels of CD8+ T-cells in patients with PDAC ( 35 ), the differential diagnosis of mass-forming pancreatitis from PDAC ( 36 ), and the grade of nonfunctioning pancreatic neuroendocrine tumors ( 37 ). Pathologically, the squamous component of PASC has been shown to express TP63, TP40, and CK5/6 and present with dense and eosinophilic cytoplasm, clear cell boundaries ( 38 ). Finally, five radiomics features from the gray-level size zone matrix (GLSZM) were selected for the radiomics model.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Non-enhanced magnetic resonance imaging-based radiomics model for the differentiation of pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

PurposeTo evaluate the diagnostic performance of radiomics model based on fully automatic segmentation of pancreatic tumors from non-enhanced magnetic resonance imaging (MRI) for differentiating pancreatic adenosquamous carcinoma (PASC) from pancreatic ductal adenocarcinoma (PDAC).Materials and methodsIn this retrospective study, patients with surgically resected histopathologically confirmed PASC and PDAC who underwent MRI scans between January 2011 and December 2020 were included in the study. Multivariable logistic regression analysis was conducted to develop a clinical and radiomics model based on non-enhanced T1-weighted and T2-weighted images. The model performances were determined based on their discrimination and clinical utility. Kaplan-Meier and log-rank tests were used for survival analysis.ResultsA total of 510 consecutive patients including 387 patients (age: 61 ± 9 years; range: 28–86 years; 250 males) with PDAC and 123 patients (age: 62 ± 10 years; range: 36–84 years; 78 males) with PASC were included in the study. All patients were split into training (n=382) and validation (n=128) sets according to time. The radiomics model showed good discrimination in the validation (AUC, 0.87) set and outperformed the MRI model (validation set AUC, 0.80) and the ring-enhancement (validation set AUC, 0.74).ConclusionsThe radiomics model based on non-enhanced MRI outperformed the MRI model and ring-enhancement to differentiate PASC from PDAC; it can, thus, provide important information for decision-making towards precise management and treatment of PASC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The classification and survival prediction of the radiomics model. shown to express TP63, TP40, and CK5/6 and present with dense and eosinophilic cytoplasm, clear cell boundaries (38). Finally, five radiomics features from the gray-level size zone matrix (GLSZM) were selected for the radiomics model.…”

Section: A B D Cmentioning

confidence: 99%

Non-enhanced magnetic resonance imaging-based radiomics model for the differentiation of pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Several criteria were employed in various studies to determine the extent of squamous differentiation, including any squamous component (8), more than 10% squamous differentiation (9)(10)(11), more than 25% squamous differentiation (4), and more than 30% squamous differentiation (5,6). It is common for researchers to include squamous differentiation in the GBASC cohort since there are much fewer cases of GBASC than there are of mixed-difference tumors in the breasts and pancreas (12). For this study, we thus defined GBASC as including any component of squamous differentiation.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic response analysis for patients with adenosquamous carcinoma of the gallbladder: data analysis based on the Surveillance, Epidemiology, and End Results (SEER) database

Fang¹,

Wang²,

Wang³

et al. 2023

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Adenosquamous carcinoma of the gallbladder (GBASC) is a rare histological variant without defined appropriate clinical measures.Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, data on a cohort of patients with GBASC were collected from 21 cancer registries between 1975 and 2018. We used Kaplan-Meier analysis to evaluate the effectiveness of different treatment regimens on patients with GBASC. Then we used Cox proportional hazards regression method to determine the prognostic factors for cancer-specific survival (CSS) of GBASC patients.Results: A total of 388 patients with GBASC were identified: 80 patients diagnosed as early stage and 308 patients diagnosed as advanced stage. For early-stage GBASC, radical lymph node dissection improved the CSS significantly; for advanced-stage GBASC, radical surgery, nonradical surgery, lymph node dissection, chemotherapy, and radiotherapy improved the CSS significantly. Surgery, lymph node dissection, radiation, chemotherapy, age, race, and the American Joint Committee on Cancer (AJCC) stage were the independent risk factors for the CSS of GBASC patients.Conclusions: Radical intraoperative lymph node dissection provided a survival benefit for patients with early-stage GBASC, whereas chemotherapy and radiotherapy provided no significant benefit; surgical treatment, more complete lymph node dissection, radiotherapy, and chemotherapy provided survival benefits for patients with advanced GBASC. The prognosis for GBASC patients is affected by the factors of surgery, lymph node dissection, radiation, chemotherapy, age, race, and the AJCC stage.

show abstract

A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells

Bahmaie,

Ozensoy Guler,

Simsek

2024

The Journal of Liquid Biopsy

View full text Add to dashboard Cite

Research advances and treatment perspectives of pancreatic adenosquamous carcinoma

Cited by 5 publications

References 89 publications

Non-enhanced magnetic resonance imaging-based radiomics model for the differentiation of pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma

Non-enhanced magnetic resonance imaging-based radiomics model for the differentiation of pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma

Therapeutic response analysis for patients with adenosquamous carcinoma of the gallbladder: data analysis based on the Surveillance, Epidemiology, and End Results (SEER) database

A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells

Contact Info

Product

Resources

About